Home

Steven St Peter

CIK 1352447 · PRESIDENT AND CEO · last filed 2018-12-17

Steven St Peter is a PRESIDENT AND CEO who has filed 45 SEC Form 4 insider transactions across 4 companies since 2007. The most recent filing shows the insider sold $269.8K of PETX on Dec 17, 2018. Across all open-market trades the lifetime net is −$5.9M, making them a net seller over the disclosed history. 27 SEC filings were submitted jointly with John Vander Vort.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

4

Total Filings

45

Lifetime Open-Market Net

-$5.90M

Filer Profile

Reported Address
MPM CAPITAL
200 CLARENDON STREET 54TH FLOOR
BOSTON, MA 02116
Related Filers
John Vander Vort — 27 joint filings, latest 2012-02-03
VAUGHN M KAILIAN — 24 joint filings, latest 2012-02-03
Ashley L. Dombkowski — 23 joint filings, latest 2011-05-19
LUKE EVNIN — 21 joint filings, latest 2012-02-03
ANSBERT GADICKE — 19 joint filings, latest 2009-11-13
James Paul Scopa — 18 joint filings, latest 2012-02-03
Todd Foley — 5 joint filings, latest 2012-02-03
Pacira BioSciences, Inc. — 4 joint filings, latest 2011-11-22
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ARATANA THERAPEUTICS, INC. (PETX) Delisted PRESIDENT AND CEO 603,623 — — -$5.86M 26 2018-12-17
Altimmune, Inc. (PIP) Delisted Director 18,500 — — $41.2K 13 2017-01-05
Omrix Biopharmaceuticals, Inc. (OMRI) Delisted Director 4,000 — — -$81.1K 3 2008-09-05
HELICOS BIOSCIENCES CORP (HLCS) Delisted Director — — — $0 1 2007-07-31

Recent Filings

45 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2018-12-17 ARATANA THERAPEUTICS, INC. (PETX) Delisted Sell (S) −46,094 -$269.8K EDGAR
2018-10-31 ARATANA THERAPEUTICS, INC. (PETX) Delisted Sell (S) −11,513 -$67.5K EDGAR
2018-09-21 ARATANA THERAPEUTICS, INC. (PETX) Delisted Sell (S) −75,000 -$454.3K EDGAR
2018-07-30 ARATANA THERAPEUTICS, INC. (PETX) Delisted Sell (S) −11,513 -$49.8K EDGAR
2018-05-01 ARATANA THERAPEUTICS, INC. (PETX) Delisted Sell (S) −11,513 -$57.6K EDGAR
2018-04-30 ARATANA THERAPEUTICS, INC. (PETX) Delisted Sell (S) +11,513 $57.6K EDGAR
2018-02-01 ARATANA THERAPEUTICS, INC. (PETX) Delisted Sell (S) −19,367 -$92.3K EDGAR
2018-01-26 ARATANA THERAPEUTICS, INC. (PETX) Delisted Grant (A) +135,600 $0 EDGAR
2017-12-21 ARATANA THERAPEUTICS, INC. (PETX) Delisted Exer (M) +26,667 $83.7K EDGAR
2017-11-13 ARATANA THERAPEUTICS, INC. (PETX) Delisted Sell (S) −50,000 -$350.0K EDGAR
Showing 1–10 of 45
Page 1 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.